NASDAQ:XBIT XBiotech (XBIT) Stock Price, News & Analysis → Could Your Accounts Be Frozen? (From Allegiance Gold) (Ad) Free XBIT Stock Alerts $8.49 +0.47 (+5.86%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$8.09▼$8.7350-Day Range$5.91▼$9.8952-Week Range$3.21▼$9.96Volume45,313 shsAverage Volume96,271 shsMarket Capitalization$258.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get XBiotech alerts: Email Address Ad Weiss RatingsFW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.Click here. About XBiotech Stock (NASDAQ:XBIT)XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.Read More XBIT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XBIT Stock News HeadlinesMay 4, 2024 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Stock Price Crosses Above Fifty Day Moving Average of $7.66April 26, 2024 | americanbankingnews.comXBiotech (NASDAQ:XBIT) Stock Price Crosses Above 50 Day Moving Average of $7.45May 4, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...April 25, 2024 | finance.yahoo.comXBiotech Inc. (XBIT) Stock Price, News, Quote & History - Yahoo FinanceApril 24, 2024 | money.usnews.comXBiotech IncMarch 20, 2024 | finance.yahoo.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 44% stake, while 44% is held by insidersMarch 18, 2024 | investorplace.comXBIT Stock Earnings: XBiotech Reported Results for Q4 2023March 8, 2024 | finance.yahoo.comThe Zacks Analyst Blog Highlights Quince Therapeutics and XBiotechMay 4, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...February 17, 2024 | finance.yahoo.comXBIT Mar 2024 5.000 callJanuary 18, 2024 | morningstar.comXBiotech Inc XBITJanuary 8, 2024 | bizjournals.comA top Austin biopharmaceutical company is doubling down on its Austin campusJanuary 4, 2024 | finance.yahoo.comXBiotech to Begin Constructing New R&D Facility on its 48-acre CampusDecember 15, 2023 | msn.comARCT, EHTH and CRTO are among after hour moversDecember 5, 2023 | finance.yahoo.comCompanies Like XBiotech (NASDAQ:XBIT) Are In A Position To Invest In GrowthNovember 14, 2023 | finanznachrichten.deXBiotech Inc.: Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid ArthritisNovember 14, 2023 | finance.yahoo.comDr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid ArthritisSeptember 26, 2023 | finance.yahoo.comXBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeAugust 8, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialAugust 8, 2023 | finance.yahoo.comXBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialJune 30, 2023 | thestreet.comXBiotech Cancer Drug Survival Claim Falls Apart Under ScrutinyMay 23, 2023 | finanznachrichten.deXBiotech Inc.: FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 22, 2023 | finance.yahoo.comFDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsMay 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesMay 17, 2023 | finance.yahoo.comXBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesApril 17, 2023 | finanznachrichten.deXBiotech Inc.: XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeApril 17, 2023 | finance.yahoo.comXBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeSee More Headlines Receive XBIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XBiotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2024Today5/04/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XBIT CUSIPN/A CIK1626878 Webwww.xbiotech.com Phone(512) 386-2900Fax512-386-5505Employees82Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,560,000.00 Net MarginsN/A Pretax Margin-7,401.67% Return on Equity-10.82% Return on Assets-10.52% Debt Debt-to-Equity RatioN/A Current Ratio33.07 Quick Ratio33.07 Sales & Book Value Annual Sales$4.01 million Price / Sales64.47 Cash FlowN/A Price / Cash FlowN/A Book Value$7.19 per share Price / Book1.18Miscellaneous Outstanding Shares30,450,000Free Float21,803,000Market Cap$258.52 million OptionableOptionable Beta1.49 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. John Simard (Age 62)Founder, President, CEO & Chairman Comp: $4.67MDr. Sushma Shivaswamy Ph.D. (Age 46)Chief Scientific Officer Comp: $381.24kMs. Angela Hu (Age 40)Director of Finance, Principal Financial & Accounting Officer and Financial Controller Key CompetitorsAldeyra TherapeuticsNASDAQ:ALDX2seventy bioNASDAQ:TSVTFoghorn TherapeuticsNASDAQ:FHTXImmutepNASDAQ:IMMPRenovaroNASDAQ:RENBView All CompetitorsInstitutional OwnershipNational Bank of Canada FIBought 24,347 shares on 2/6/2024Ownership: 0.080%View All Institutional Transactions XBIT Stock Analysis - Frequently Asked Questions How have XBIT shares performed in 2024? XBiotech's stock was trading at $4.00 at the beginning of 2024. Since then, XBIT stock has increased by 112.3% and is now trading at $8.49. View the best growth stocks for 2024 here. When is XBiotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our XBIT earnings forecast. How were XBiotech's earnings last quarter? XBiotech Inc. (NASDAQ:XBIT) released its earnings results on Friday, March, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter. What ETF holds XBiotech's stock? Amplify Treatments, Testing and Advancements ETF holds 7,198 shares of XBIT stock, representing 0.64% of its portfolio. What is John Simard's approval rating as XBiotech's CEO? 20 employees have rated XBiotech Chief Executive Officer John Simard on Glassdoor.com. John Simard has an approval rating of 58% among the company's employees. This puts John Simard in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of XBiotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Block (SQ). When did XBiotech IPO? XBiotech (XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO. How do I buy shares of XBiotech? Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XBIT) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.